Author:
Zhan Mengyao,Xue Hao,Wang Yuting,Wu Zhuchao,Wen Qin,Shi Xinling,Wang Jianming
Abstract
Abstract
Objectives
Identifying prognostic factors helps optimize the treatment regimen and promote favorable outcomes. We conducted a prospective cohort study on patients with pulmonary tuberculosis to construct a clinical indicator-based model and estimate its performance.
Methods
We performed a two-stage study by recruiting 346 pulmonary tuberculosis patients diagnosed between 2016 and 2018 in Dafeng city as the training cohort and 132 patients diagnosed between 2018 and 2019 in Nanjing city as the external validation population. We generated a risk score based on blood and biochemistry examination indicators by the least absolute shrinkage and selection operator (LASSO) Cox regression. Univariate and multivariate Cox regression models were used to assess the risk score, and the strength of association was expressed as the hazard ratio (HR) and 95% confidence interval (CI). We plotted the receiver operating characteristic (ROC) curve and calculated the area under the curve (AUC). Internal validation was conducted by 10-fold cross-validation.
Results
Ten significant indicators (PLT, PCV, LYMPH, MONO%, NEUT, NEUT%, TBTL, ALT, UA, and Cys-C) were selected to generate the risk score. Clinical indicator-based score (HR: 10.018, 95% CI: 4.904–20.468, P < 0.001), symptom-based score (HR: 1.356, 95% CI: 1.079–1.704, P = 0.009), pulmonary cavity (HR: 0.242, 95% CI: 0.087–0.674, P = 0.007), treatment history (HR: 2.810, 95% CI: 1.137–6.948, P = 0.025), and tobacco smoking (HR: 2.499, 95% CI: 1.097–5.691, P = 0.029) were significantly related to the treatment outcomes. The AUC was 0.766 (95% CI: 0.649–0.863) in the training cohort and 0.796 (95% CI: 0.630–0.928) in the validation dataset.
Conclusion
In addition to the traditional predictive factors, the clinical indicator-based risk score determined in this study has a good prediction effect on the prognosis of tuberculosis.
Funder
Yancheng Medical Science and Technology Development Program
National Natural Science Foundation of China
Medical Research Project of Jiangsu Health Commission
Nanjing Major Science and Technology Project
Publisher
Springer Science and Business Media LLC
Reference37 articles.
1. WHO. Global tuberculosis report 2021. Geneva: World Health Organization; 2021.
2. Borisov AS, Bamrah Morris S, Njie GJ, Winston CA, Burton D, Goldberg S, Yelk Woodruff R, Allen L, LoBue P, Vernon A. Update of recommendations for use of once-weekly isoniazid-rifapentine regimen to treat latent Mycobacterium tuberculosis infection. MMWR Morbidity and mortality weekly report. 2018;67(25):723–6.
3. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recommendations and reports: Morbidity and mortality weekly report Recommendations and reports. 2000, 49(RR-6):1–51.
4. Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in south african mineworkers. Lancet. 2001;358(9294):1687–93.
5. Panjabi R, Comstock GW, Golub JE. Recurrent tuberculosis and its risk factors: adequately treated patients are still at high risk. Int J tuberculosis lung disease: official J Int Union against Tuberculosis Lung Disease. 2007;11(8):828–37.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献